Figma stock opens for trade at $85, up 158% from where IPO priced
At the open of trading on Thursday, the company was worth more than $45 billion. Shares were halted for trade within moments of the stock opening due to volatility.
Thursday's trade showed that demand remains strong for new issues, with the company pricing its IPO above expectations for a range of $30-$32.
The company is set to raise roughly $1.2 billion in a sale of 36.94 million shares, split between the company's sale of 12.47 million shares and existing shareholders' sale of 24.46 million shares.
Figma, helmed by CEO Dylan Field, is set to be the latest indicator of an IPO market that has been strong in 2025, with tech darlings like Circle (CRCL) and CoreWeave (CRWV) seeing shares soar after public debuts earlier this year.
Figma's IPO comes after the company abandoned plans to sell itself to digital software giant Adobe (ADBE) in 2023 for $20 billion after European regulators raised anti-competition concerns about the merger between two digital design giants.
The company's IPO plans have been closely watched on Wall Street.
The Street's $30-$32 pricing expectations, which Figma has now exceeded, were already a raise from Figma's own prediction of a $25-$28 pricing.
Should Figma stock soar after opening for trade this morning, the tech company will follow in the footsteps of Circle, which saw shares rise 168% from its IPO price on its first day of trading.
Circle is now up more than 510% since its open in June. Fellow IPO darling CoreWeave (CRWV), which notched only a marginal gain on its first trading session, is up more than 160% since its March debut.
Figma's revenue has grown by 46% year over year. More than three-quarters of Forbes 2000 companies use the design software maker's products, according to Figma's offering documents.
The success of IPOs like Circle has pushed the market back toward the year of dealmaking Wall Street M&A bankers had been calling for until that was thwarted by a widespread market freeze following tariff uncertainty in April.
The Renaissance IPO Index, run by IPO data firm Renaissance Capital and tracking public offering performance, came back after an "April freefall" to deliver an "explosive rally to end [Q2] up 20%, outperforming the S&P 500 (+11%)," according to the firm's Q2 quarterly review.
Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at jake.conley@yahooinc.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 576% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 410% gain in the last three months. The longer term returns have not been as good, with the stock price only 6.4% higher than it was three years ago. We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year NeuroScientific Biopharmaceuticals grew its earnings per share (EPS) by 54%. The share price gain of 576% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 70.06 also points to this optimism. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. A Different Perspective We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 576% over one year. That's better than the annualised return of 1.2% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with NeuroScientific Biopharmaceuticals (including 2 which are potentially serious) . For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
If You'd Invested $1,000 in Solana 5 Years Ago, Here's How Much You'd Have Today
Key Points Solana runs on a proof-of-stake network that is one of the fastest in the crypto world. The network is already processing thousands of transactions per second. The technical strength of the network has made it a home run for investors. 10 stocks we like better than Solana › Only launched about 5.5 years ago, Solana (CRYPTO: SOL) is now the sixth-largest cryptocurrency in the world with a market cap of over $96 billion as of July 30. Many investors see immense potential in Solana's network. It's one of the few cryptocurrencies to operate on a proof-of-stake (PoS) mechanism to govern the network. After realizing how energy-intensive the traditional crypto-mining, proof-of-work (PoW) system had become on Bitcoin, the world's largest cryptocurrency, several crypto networks transitioned to PoS. Instead of using high computing power to solve a puzzle like with PoW, PoS has investors stake their tokens to the network, and then assigns them at random to validate transactions and mint new tokens. The more tokens one stakes, the higher the chance they have of being selected and also earning rewards. Even more unique, Solana's network also has a proof-of-history mechanism that essentially creates a sequential record of transactions, enabling even faster transactions on the network. As a result, Solana's network can process thousands of transactions per second (TPS), but it has the theoretical potential to process up to 65,000 TPS, if not more. This gives Solana and its network immense potential to disrupt the global payments system. Investors have done well While volatile like most cryptocurrencies, Solana has been a huge winner for investors that bought the token five years ago. The technical strength of its network has made Solana one of the few altcoins that investors see a strong use case for. Roughly five years ago, Solana traded for just $1.73. Today, it trades for over $179. That's a gain of roughly 10,264%. So, if you invested $1,000 in Solana five years ago, you now have $103,636! That's simply incredible. Investors aren't likely to find too many investments like that in their lifetime. Should you invest $1,000 in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bram Berkowitz has positions in Bitcoin. The Motley Fool has positions in and recommends Bitcoin and Solana. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Solana 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Washington Post
18 minutes ago
- Washington Post
Cowboys owner Jerry Jones dismisses Micah Parsons' trade request as negotiation talk
OXNARD, Calif. — Dallas Cowboys owner and general manager Jerry Jones does not intend to trade Micah Parsons after the star defensive end said he wants to leave the team amid a breakdown in negotiating a contract extension. 'Surely you guys have been around this stuff and know how to recognize negotiation talk, that type of thing. And so that's where I put that,' Jones said after practice Saturday, one day after Parsons posted on social media to request a trade .
